The biomedical industry chain is setting off a wave of IPOs, and unique technologies and platforms are the core driving force

In recent days, the heat of biomedical industry chain enterprises in the capital market can not be described as not high

On September 1, BIOSET was listed on the main board of the Hong Kong Stock Exchange, becoming the first gene editing stock with a total market capitalization of HK$

Biomedical industry chain companies are intensively landing on the capital market, and the heat of the track is breaking out

What signals have been released by the intensive listing of enterprises in the biomedical industry chain?

What signals have been released by the intensive listing of enterprises in the biomedical industry chain?

The listing of BEOSAItu and Opimai is actually a microcosm

The listing of BEOSAItu and Opimai is actually a microcosm

On the one hand, the outbreak of the new crown epidemic and the changes in the international situation have lengthened the supply cycle of products required for pharmaceutical research and development and production, and supply chain security issues have really been placed in front of the

The outbreak of the new crown epidemic and changes in the international situation have extended the lead time of products needed for pharmaceutical research and development and production, and supply chain safety issues

On the other hand, medical insurance collection has a profound impact on the domestic pharmaceutical industry, with the gradual normalization, institutionalization and expansion of collection bidding, the cost pressure brought by collection and procurement is being transmitted to the upstream of the industrial chain, which will inevitably promote the reduction of costs, and biopharmaceutical enterprises have more incentives to choose high-quality and inexpensive domestic products to further reduce production and research and development costs

The cost pressure brought by collection and mining is being transmitted to the upstream of the industrial chain, which will inevitably promote the reduction of costs.

The innovation ability of the domestic biomedical industry has gradually increased

Policies, environment, technology development and market demand have all spawned the domestic biomedical industry chain heat climbing, a number of pharmaceutical industry chain enterprises towards IPO

Look back at the two companies

IT took 6 years to independently develop a unique chromosome engineering technology SUPCE, breaking through the size limit of gene editing fragments, based on which to develop the full human antibody mouse RenMice platform, and build a five major antibody technology platform for whole human monoclonal antibody, double antibody, double antibody ADC, GPCR antibody and TCR-like antibody, forming the core competitiveness

The development of the fully human antibody mouse RenMice platform forms the core competitiveness

As a leading biomedical media company in China, OPMEI not only has independently developed patents and formulas, breaking the monopoly of foreign giants in the field of serum-free media, but also quickly occupying the domestic market

On the basis of medium process research and development and product optimization, the company has gradually created CDMO service technology platforms such as cell line construction platform and instantaneous transfection platform, and through the business model of organic integration of culture medium + CDMO, it reduces the production cost of antibody drugs with high-quality culture media to achieve import substitution, and empowers innovative drug development

CDMO service technology platforms such as cell line construction platforms and instantaneous transfection platforms

It can be seen that both companies have unique technologies in their respective fields, and further strengthen their barrier advantages by creating technology platforms, making them stand out

Both companies have unique technologies in their respective fields and have further strengthened their barriers by building technology platforms to make them stand out from

Technical barriers and platform effects are the focus of industrial chain investment

In summary, from the external point of view, in recent years, the strength of domestic biomedical enterprises has been continuously enhanced, the purchase cycle and supply chain safety issues under the background of the epidemic, as well as the cost pressure caused by collection and procurement has been transmitted upstream, which has provided an excellent opportunity
for the development of the pharmaceutical industry chain.
Analyzing internal reasons, unique technical advantages and platform effects are the key
to enterprises to establish industry barriers and enhance core competitiveness.

Further, the prosperity of the industrial chain provides a rich fertile ground for the development of biomedicine, and the promotion of capital is also an indispensable part
of it.

The prosperity of the industrial chain provides a rich fertile ground for the development of biomedicine, and the promotion of capital is also an indispensable part of
it.

From the listing of two companies, we observed that there is the same early VC investment institution behind it: Materia Medica Capital
.
As early as the beginning of 2018, Materia Medica Capital invested in BIOSET and Yuhe Pharmaceutical, and continued to add multiple rounds in the follow-up, which promoted its listing process
.
In 2020, as one of the investors, Materia Medica Capital participated in opal Mai's Series B financing to help it build a biopharmaceutical industry chain ecology
.

It is reported that in addition to the layout of the pharmaceutical industry chain, Materia Medica Capital has also invested in several industrial chain related enterprises
such as Huagong Biological, Kaiyou Biological, Jingyu Group, Dingzhi Biological, and Jingcheng Pharmaceutical.
According to the limited analysis of public information, these companies often have relatively high technical barriers and platform advantages
.

In addition to BIOSAItu and Opimai, Materia Medica Capital has also invested in several industry chain-related enterprises
such as Huagong Biology, Kaiyou Biological, Jingyu Group, Dingzhi Biologics, and Jingcheng Pharmaceutical.
It has relatively high technical barriers and platform advantages
.

Huagong Biology focuses on innovative 3D cell technology, and the cell culture 3D microcarrier technology transformed by the research team of Professor Du Yanan of Tsinghua University School of Medicine has broken the monopoly of imports for many years, and has served hundreds of leading customers in the fields of stem cells, vaccines, gene therapy, immunotherapy, etc.
, and has reached strategic cooperation agreements
with a number of medical institutions and scientific research universities.

Huagong Biologics' core product, 3D TableTrix microcarrier (microcarrier), is an independent innovation type of pharmaceutical excipient-level microcarrier that can be used for cell drug development, and is also the only microcarrier in the world that has obtained the qualification of two-way pharmaceutical excipients from the US Food and Drug Administration and the China Food and Drug Administration
.
As a porous microsphere, its chemical and physical properties are precise and controllable, and the cell microenvironment can be customized according to the cell type
.
With specific lysis techniques, 100% harvesting of cells can be achieved
.

The 3D TableTrix microcarrier (microcarrier) is the only microcarrier in the world that has obtained both the US Food and Drug Administration and the China Food and Drug Administration bidirectional pharmaceutical excipient qualification
.

Kaiyou Biotech is the upstream GMP enzyme raw material provider
for the biomedical and gene therapy industries.
Relying on sams (Structure Aided design and Multiplex Screening), an innovative functional recombinant protein and antibody R&D and production platform independently developed by kaiwa, Kaiyou Has established stable business cooperation with more than 300 innovative antibody drug research and development, cell, gene therapy and diagnostic companies at home and abroad, and successfully assisted many companies in entering the clinic
with new drug products.

Sams (Structure Aided design and Multiplex Screening), an innovative R&D and production platform for functional recombinant proteins and antibodies developed in-house.

The strategic position of upstream raw materials for new drug research and development is becoming increasingly important, and Kaiyou Bio's unique innovative functional recombinant protein and antibody research and development and production platform can solve the key problems of localization of the domestic biomedical industry supply chain, and has become a well-known antigen protein brand in the market and has entered rapid development
.

Analyzing these, it can be seen that in addition to investing in innovative medicine and cross-innovative medical devices and diagnostics, Materia Medica Capital is also making a systematic layout
in the biomedical industry chain.
On the one hand, the investment in the industrial chain can help Materia Medica better empower the innovative enterprises that have been invested, on the other hand, many innovative and new drug companies that have been laid out by Materia Medica can also become customers
of these industrial chain companies.
It is understood that after the investment, Materia Medica has repeatedly promoted the cooperation
between its invested pharmaceutical enterprises and BIOSAItu, Opmani, Huagong and so on.

The investment in the industrial chain can help Materia Medica better empower the invested innovative enterprises Many innovative and new drug companies that have been laid out by Materia Medica can also become customers of these industrial chain companies

From the overall trend point of view, the international situation is increasingly turbulent, the epidemic normalization development, domestic demand growth, technological upgrading, the next 3-5 years is a period of rapid growth of biomedical enterprises, pharmaceutical industry chain enterprises deserve attention, unique technology and platform effect is the core driving force
.